US20220002776A1 - Cell Expression System - Google Patents
Cell Expression System Download PDFInfo
- Publication number
- US20220002776A1 US20220002776A1 US17/211,625 US202117211625A US2022002776A1 US 20220002776 A1 US20220002776 A1 US 20220002776A1 US 202117211625 A US202117211625 A US 202117211625A US 2022002776 A1 US2022002776 A1 US 2022002776A1
- Authority
- US
- United States
- Prior art keywords
- cell
- expression
- host cell
- hgh
- cho
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 115
- 239000013604 expression vector Substances 0.000 claims abstract description 58
- 108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 56
- 108010022394 Threonine synthase Proteins 0.000 claims abstract description 15
- 102000004419 dihydrofolate reductase Human genes 0.000 claims abstract description 15
- 230000007812 deficiency Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 207
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 53
- 239000000854 Human Growth Hormone Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 229960000106 biosimilars Drugs 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 229960000598 infliximab Drugs 0.000 claims description 15
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 13
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 102000003951 Erythropoietin Human genes 0.000 claims description 5
- 108090000394 Erythropoietin Proteins 0.000 claims description 5
- 229940105423 erythropoietin Drugs 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 4
- 102000018594 Tumour necrosis factor Human genes 0.000 claims description 4
- 108050007852 Tumour necrosis factor Proteins 0.000 claims description 4
- 229960002964 adalimumab Drugs 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 229960005395 cetuximab Drugs 0.000 claims description 4
- 229960000403 etanercept Drugs 0.000 claims description 4
- 229960003876 ranibizumab Drugs 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 102000001301 EGF receptor Human genes 0.000 claims description 2
- 108060006698 EGF receptor Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000004115 adherent culture Methods 0.000 claims 1
- 238000004114 suspension culture Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 104
- 102000004169 proteins and genes Human genes 0.000 abstract description 58
- 238000010367 cloning Methods 0.000 abstract description 31
- 239000003623 enhancer Substances 0.000 abstract description 22
- 241000700605 Viruses Species 0.000 abstract description 18
- 108091026890 Coding region Proteins 0.000 abstract description 13
- 239000003550 marker Substances 0.000 abstract description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 8
- 108091005904 Hemoglobin subunit beta Proteins 0.000 abstract description 5
- 229960000723 ampicillin Drugs 0.000 abstract description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 abstract description 5
- 102100021519 Hemoglobin subunit beta Human genes 0.000 abstract description 3
- 230000002477 vacuolizing effect Effects 0.000 abstract description 3
- 108700029942 Megaloblastic Anemia due to Dihydrofolate Reductase Deficiency Proteins 0.000 abstract description 2
- 208000015806 constitutional megaloblastic anemia with severe neurologic disease Diseases 0.000 abstract description 2
- 230000010076 replication Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 42
- 229940079593 drug Drugs 0.000 description 37
- 239000013598 vector Substances 0.000 description 36
- 230000001105 regulatory effect Effects 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 17
- 101150074155 DHFR gene Proteins 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 230000008488 polyadenylation Effects 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 230000012010 growth Effects 0.000 description 13
- 241000701022 Cytomegalovirus Species 0.000 description 12
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 12
- 229960000074 biopharmaceutical Drugs 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 229960000485 methotrexate Drugs 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 230000007773 growth pattern Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 5
- 239000003168 generic drug Substances 0.000 description 5
- 239000012212 insulator Substances 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010370 cell cloning Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000009133 Arylsulfatases Human genes 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 2
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
- 101710113864 Heat shock protein 90 Proteins 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 101150073130 ampR gene Proteins 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 108060007951 sulfatase Proteins 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001136782 Alca Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000002435 Cyclin T Human genes 0.000 description 1
- 108010068106 Cyclin T Proteins 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 239000012743 FreeStyle Max reagent Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101001035782 Gallus gallus Hemoglobin subunit beta Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 1
- 101150027568 LC gene Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 101150114527 Nkx2-5 gene Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 101100353123 Rattus norvegicus Ppp1r15a gene Proteins 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000013354 cell banking Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 108010066540 copper thionein Proteins 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 108010057988 ecdysone receptor Proteins 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 229940063135 genotropin Drugs 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 101150024821 tetO gene Proteins 0.000 description 1
- 101150061166 tetR gene Proteins 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
- C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
- C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
Definitions
- the present invention relates to expression systems, in particular the invention relates to expression systems for the production of biological therapeutics.
- Expression systems for the production of biological therapeutics or biopharmaceuticals generally consist of a nucleic acid vector construct encoding the desired recombinant therapeutic and a chosen host cell.
- the vector is introduced into the host cell and the endogenous cell machinery is utilised for the production of the desired therapeutic i.e. the desired recombinant protein.
- the intricacies in establishing an efficient and reliable expression system for the production of approvable biological therapeutics are manifold. However, well-established expression systems may provide cost-effective alternatives for the production of pharmaceutical products otherwise difficult to obtain.
- Efficiency of the system itself depends on a large variety of factors including the design of the vector and the choice of host cell.
- Nucleic acid vectors used in expression systems comprise plasmids, cosmids, Yeast Artificial Chromosomes (YACs), Bacterial Artificial Chromosomes (BACs), retroviral, adenoviral and lentiviral vectors. These vectors differ in many characteristics, such as their capacity to accommodate different sized nucleic acid inserts, their most efficient introduction method into the host cell and specifically in their utilisation of the endogenous cell machineries of different types of host cells to ensure sufficient expression of the desired protein.
- YACs Yeast Artificial Chromosomes
- BACs Bacterial Artificial Chromosomes
- retroviral adenoviral and lentiviral vectors.
- regulatory elements commonly present in such expression vectors influence transcription, translation as well as protein synthesis of selection markers and of sequences encoding the desired biological therapeutic.
- Such regulatory elements include, but are not limited to, promoters, terminators, modifiers, insulators, spacers, regulatory protein binding sites, introns, inducers, etc.
- TK thymidine kinase
- actin actin promoter
- GPDH glyceraldehyde 3-phosphate dehydrogenase
- GPDH glyceraldehyde 3-phosphate dehydrogenase
- SV40 simian vacuolating virus 40
- CMV cytomegalovirus
- AcNPV Autographa californica nuclear polyhedrosis virus
- ⁇ 3GAL-T5 ⁇ 3-galactosyltransferase 5
- Known promoters also include inducible promoters such as the heat shock protein 70 (HSP70) promoter (stress induced), the heat shock protein 90 (HSP90) promoter (stress induced), the alcoholdehydrogenase I (alcA) promoter (alcohol induced), the activating copper-metallothionein expression (ACEl) promoter (metal induced), the small subunit of ribulose-1,5-bisphophate-carboxylase (SSU1) promoter (light induced), the hypoxia induced factor 1 ⁇ (hif1 ⁇ ) promoter (hypoxia induced), the inducer of meiosis 2 (IME2) promoter (starvation induced), the glucocorticoid receptor (hormone induced), the estrogen receptor (hormone induced) and the ecdysone receptor (hormone induced).
- HSP70 heat shock protein 70
- HSP90 heat shock protein 90
- alcA alcoholdehydrogenase I
- ACEl activ
- cell type/tissue specific promoters such as the nkx2.5 promoter (heart cells), the islet 1 promoter (pancreatic cells), the MyoD promoter (muscle cells), the cluster of differentiation 2 (CD2) promoter (T-cells) and the collagen II promoter (cartilage), are known to change their level of activity in response to cell type specific stimuli or to progression through developmental stages.
- RNA Polymerase II terminator such as the RNA Polymerase II terminator, the small nucleolar RNA 13 (snR13) terminator, the bovine growth hormone (BGH) terminator, the simian virus 40 (SV 40) terminator and the thymidine kinase (TK) terminator, may provide suitable polyadenylation signals.
- BGH bovine growth hormone
- SV 40 simian virus 40
- TK thymidine kinase
- Known modifier and insulator elements include the tetracycline operator/receptor (tetO/tetR) system, the upstream activating sequence of the galactose dependent GAL4 transcription factor (GAL4 UAS), the adenovirus early region B1 TATA box, binding sites for the herpes simplex virus (HSV) regulatory protein VP16, the 5′HS4 chicken ⁇ -globin insulator, the paternally expressed gene 3 (Peg3) insulator and the sea urchin arylsulfatase (ARS) gene insulator.
- tetO/tetR the upstream activating sequence of the galactose dependent GAL4 transcription factor
- GAL4 UAS galactose dependent GAL4 transcription factor
- adenovirus early region B1 TATA box binding sites for the herpes simplex virus (HSV) regulatory protein VP16
- HSV herpes simplex virus
- Peg3 paternally expressed gene 3
- Biosimilars ideally are bioequivalents of the innovator drugs and, as such, the path to regulatory approval for biosimilars is in theory less arduous than for the original innovator drug as the clinical data establishing safety and efficacy have been carried out.
- Approval of generic biopharmaceuticals is dependent on comparable dosage form, strength, route of administration, quality, performance characteristics and intended use compared with approved biopharmaceuticals (that is, the reference listed drugs).
- approved biopharmaceuticals that is, the reference listed drugs.
- FDA United States Food and Drug Administration
- AZA Abbreviated New Drug Application
- Approval also involves a bioequivalence review, which establishes that the proposed generic drug is bioequivalent to the reference-listed drug. This bioequivalency is based upon a demonstration that the rate and extent of absorption of the active ingredient in the generic drug fall within the scope of the parameter of the reference listed drug.
- a first aspect of the present invention may relates to novel expression systems and methods of employing an expression system according to the invention that may, in certain embodiments, increase the yield and decrease the cost of manufacture.
- This invention relates to methods of production of recombinant biosimilars, bio-pharmaceuticals and other desirable proteins, polypeptides and peptides using mammalian cell cultures.
- the methods of the invention involve the use of specially bioengineered mammalian cell lines for the production of complex proteins in low cost media. These cell lines have the acquired ability for autonomous growth in cheap, reproducible, fully-defined protein-free medium, with the cells expressing and secreting its growth factor requirements.
- the present invention provides an expression system for expressing a protein comprising:
- the expression system further comprises a second protein expression module, the second protein expression module including: a Cyotomegalovirus promoter being separable from a SV40 polyadenylation sequence by a second multiple cloning site for co-expression of at least two proteins from the expression modules.
- a Cyotomegalovirus promoter being separable from a SV40 polyadenylation sequence by a second multiple cloning site for co-expression of at least two proteins from the expression modules.
- the protein is the subject of a request for regulatory approval and wherein the host cell is subjected to a plurality of predetermined manipulations such that the host cell expresses said protein; and wherein information is recorded on each manipulation and each manipulation is carried out in a manner which prevents contact of the host cell with a contaminating agent; and wherein the information is used to generate a history record of the host cell for inclusion in a submission to a regulatory agency involved in assessing the safety and efficacy of drugs thereby expediting regulatory approval of the protein.
- the predetermined manipulations preferably comprise:
- Step (iii) includes growing the host cell in a medium that contains no animal or plant derived proteins or peptides and no undefined hydolysates or lysates thereby reducing contact of the host cell with a contaminating agent.
- the host cell is a Chinese Hamster Ovary (CHO) DG44 cell.
- the host CHO DG44 expresses a growth hormone.
- the growth hormone is human growth hormone.
- the protein may be a biosimilar drug.
- the present invention provides a method of managing the development of a protein expressed by the expression system according to the first aspect wherein the protein is the subject of a request for regulatory approval, the method comprising the steps of:
- the present invention provides a method of expediting regulatory approval of a protein expressed by the expression system according to the first aspect the method comprising:
- step (a) of the methods according to the second and third aspect comprises
- the recombinant vector is preferably at least in part incorporated into the genome of the host cell.
- step (iii) of the methods according to the second and third aspect includes growing the host cell in a medium that contains no animal or plant derived proteins or peptides and no undefined hydrolysates or lysates thereby reducing contact of the host cell with a contaminating agent.
- the protein is a biosimilar drug.
- Another aspect of the present invention may also provide a method for producing a desired recombinant protein, polypeptide or peptide comprising the step of: culturing a mammalian host cell in culture medium, wherein said host cell includes:
- the mammalian host cell may be any of those commonly used in the art for expressing recombinant proteins, polypeptides or peptides.
- the host cell may be a Chinese Hamster Ovary (CHO) cell such as CHO-K1, CHO-DG44 DHFR- and CHO-S. These include both adherent and suspension cell lines. Also other cell lines described within the embodiments of the present invention may also be used or preferred.
- the introduced DNA sequence(s) may be present on plasmids or otherwise integrated into the host cell chromosomes (e.g. by homologous recombination).
- the DNA sequence(s) encoding the protein, polypeptide and/or peptide factor(s) required for growth of the host cell may be selected from DNA sequences encoding human Growth Hormone (hGH), modified hGH and other growth factors and mixtures thereof. Where the host cell is CHO it is preferable that the host cell includes DNA sequences encoding human Growth Hormone (hGH).
- the invention is to be interpreted with reference to the at least one of the technical problems described or affiliated with the background art.
- the present aims to solve or ameliorate at least one of the technical problems and this may result in one or more advantageous effects as defined by this specification and described in detail with reference to the preferred embodiments of the present invention.
- FIG. 1A is a plasmid vector map entitled “pNAS-hGH” for the high level expression human growth hormone (hGH) inserted within a pNAS vector with use with NeuCHO cell line;
- FIG. 1B is an expression vector map entitled “pNeu” used for the high level expression of a single chain protein in CHO DG44 cells;
- FIG. 1C is an expression vector map entitled “pNeu-IRES-DHFR” used for the high level expression of a single chain protein in CHO DG44 cells.
- FIG. 1D is an expression vector map entitled “pNeuMAB” used for the high level expression of heavy and light antibody chains and/or recombinant monoclonal antibodies;
- FIG. 1E is an expression vector map entitled “pNeuMAB-IRES-DHFR” used for the high level expression of heavy and light antibody chains;
- FIG. 1F is an expression vector map entitled “pNeuMAB-IRES-DHFR (CMV)” used for the high level expression of heavy and light antibody chains;
- FIG. 1G is a single chain expression vector map entitled “pMAB LC (IRES-DHFR)” used for expression of light chains (LC);
- FIG. 1H is a single chain expression vector map entitled “pMAB HC” used for expression of heavy chains (HC);
- FIG. 2 depicts a growth chart demonstrating viable cell density plotted against time in respect of various cultures and cells used. Growth of DG44 Cell Lines expressing hGH compared to the Parental DG44 Cell Line and a DG44 Cell Line expressing the IGF-1 gene;
- FIG. 3 depicts a graph comparing the integral of viable cell densities against time for various preferred organisms and culture.
- FIG. 4 depicts a comparison chart showing the relative expression levels of proteins from either CHO DG44 cells or NeuCHO cell lines.
- This specification also includes the following genetic sequence information relating to expression vectors:
- Sequence No. 1 depicts the preferred coding sequence for the expression vector pMAB HC
- Sequence No. 2 depicts the preferred coding sequence for the expression vector pMAB LC(ires-dhfr);
- Sequence No. 3 depicts the preferred coding sequence for the expression vector pNAS-hGH
- Sequence No. 4 depicts the preferred coding sequence for the expression vector pNeu
- Sequence No. 5 depicts the preferred coding sequence for the expression vector pNeu-IRES-DHFR
- Sequence No. 6 depicts the preferred coding sequence for the expression vector pNeuMAB
- Sequence No. 7 depicts the preferred coding sequence for the expression vector pNeuMAB-IRES-DHFR (CMV);
- Sequence 8 depicts the preferred coding sequence for the expression vector pNeuMAB-IRES-DHFR
- biosimilars present unique issues. These issues include demonstrating that immunogenicity of the biosimilar has not been altered with respect to the reference listed drug, as well as ensuring that there are no undetected differences in the product that may potentially impact the safety and efficacy of the drug. Resolving such issues would be problematic without conducting extensive clinical trials. As such, it is likely that any application for a biosimilar would be required to demonstrate that there are no clinically meaningful differences in safety, purity and potency between the biosimilar and the reference listed drug. Moreover, an application for a biosimilar would need to provide evidence that the biosimilar has “profound similarity” (as it is impractical to demonstrate identical biological products) and that the biosimilar will produce the same clinical result as the reference listed drug in any given patient.
- biosimilars In order to gain regulatory approval, traditional generic manufacturers are required to demonstrate their drug is chemically identical to the referenced listed drug and exhibit the same properties in the human body as the original drug. In regard to biosimilars, it was previously not possible to readily demonstrate that a second-source biologic drug is unequivocally identical to an innovator drug due to the complexities of the synthesis of the drugs in potentially disparate biological systems. As such, biosimilars may exhibit slightly different properties to the original drugs that may necessitate abbreviated clinical trials in order to gain regulatory approval.
- contaminating agent refers to any agent that can potentially compromise regulatory approval of a product by a regulatory agency.
- agents may include but are not limited to adventitious agents such as viruses, bacteria, fungi and mycoplasma or proteins there from.
- cell expressed product refers to any product produced by the cell, including but not limited to proteins, peptides, glycoproteins, carbohydrates, lipids, glycolipids and nucleic acids.
- regulatory approval in so far as it relates to a product defined in the context of this specification, refers to approval from a regulatory authority which permits marketing of the product.
- safety and effectiveness studies refers to any studies conducted on a product that assess the safety and efficacy of that product for human and/or animal administration.
- clinical trials refers to studies involving either animal or humans designed assess the safety and/or efficacy of a product for a therapeutic application.
- abbreviated safety effectiveness studies and/or abbreviated clinical trials refers to studies carried out on a drug which does not involve complete phase I, II and III clinical trials. Such studies may include a bioequivalence review and a chemistry/microbiology review as defined by the US Food and Drug Administration (FDA).
- FDA US Food and Drug Administration
- biosimilar drug and ‘biosimilar” refer to a bioequivalent pharmaceutical of a drug in which patent protection has expired and where the previously protected drug has regulatory approval. In particular, this includes products prepared in cell culture by recombinant DNA technology.
- biosimilar drug and ‘biosimilar” as used herein is equivalent to the terms “follow-on biologicals” or “biosimilars”.
- protein refers to a “complete” protein as well as fragments, derivatives or homologs or chimeras thereof comprising one or more amino acid additions, deletions or substitutions, but which substantially retain the biological activity of the complete protein.
- the vector pNeu was designed for high-level expression of single chain peptides for the production of therapeutic proteins.
- the vector facilitates the insertion DNA sequences into a convenient multiple cloning site for expression in CHO cells. See Table 1 and FIG. 1A for a description of the vector and its component features.
- the 5026 bp vector encodes essential coding and regulatory sequences for the efficient expression of the recombinant gene as well as essential sequences for the selection and propagation of the plasmid in bacteria. It was designed for chemical synthesis and is void of nonessential and redundant sequences that are common components in commercial expression vectors. This allows for ease of genomic insertion with less likelihood of deletion of sequences during plasmid propagation resulting in loss of expression.
- the multiple cloning site encodes a minimum of two unique restriction sites for rapid gene cloning.
- the amino acid sequence encoding for hGH was subjected to bioinformatic analysis through proprietary third party software by GENEART AG, Regensburg Germany. Codon options were utilized to maximize expression by improving mRNA maintenance and the exploitation of available tRNA pools in CHO cells. RNA and codon optimization was performed on the coding sequences. The gene was analysed with respect to splice site recognition, mRNA stability, presence of ribosomal entry sites, mRNA secondary structures, self-homology for the purpose of increasing gene expression in CHO cells. The hGH gene was cloned into pNAS using AgeI and EcoRV restriction sites using methods well known in the art.
- the pNeuMAB vector was designed for the cloning and expression of recombinant monoclonal antibodies.
- the DNA encoding heavy and light chains are configured in the vector as two distinct and tandem transcription units. See Table 1 and FIG. 1B for a description of the vector and its component features.
- HC heavy chain
- LC light chain
- Codon options were utilized to maximize expression by improving mRNA maintenance and the exploitation of available tRNA pools in CHO cells.
- RNA and codon optimization was performed on the coding sequences.
- the genes were analysed with respect to splice site recognition, mRNA stability, presence of ribosomal entry sites, mRNA secondary structures, self-homology for the purpose of increasing gene expression in CHO cells.
- the synthetic gene encoding for the heavy chain of Infliximab was assembled from synthetic oligonucleotides and/or PCR products. The fragment was cloned into pGA14 (ampR) using AscI and PacI restriction sites. The plasmid DNA was purified (Pure YieldTM Plasmid Midiprep, Promega) from transformed bacteria and concentration determined by UV spectroscopy. The final construct was verified by sequencing. The sequence congruence within the used restriction sites was 100%.
- the synthetic cDNA sequence encoding heavy chain of Infliximab was designed to incorporate unique restriction sites Age I and Eco RV at the 5′ and 3′ ends respectively for directional cloning into the first multiple cloning site of NeuClone's antibody expression vector, pNeuMAB digested with the same restriction sites.
- the synthetic gene encoding the light chain of Infliximab was assembled from synthetic oligonucleotides and/or PCR products. The fragment was cloned into pGA18 (ampR) using AscI and PacI restriction sites. The plasmid DNA was purified (Pure YieldTM Plasmid Midiprep, Promega) from transformed bacteria and concentration determined by UV spectroscopy. The final construct was verified by sequencing. The sequence congruence within the used restriction sites was 100%.
- the synthetic cDNA sequence encoding light chain of Infliximab incorporates the unique restriction sites Sal I and Mlu I at the 5′ and 3′ ends respectively for directional cloning into the second multiple cloning site of NeuClone's antibody expression vector, pNeuMAB digested with the same restriction sites.
- One of the preferred methods by which the expression vector encoding human growth hormone into the host CHO DG44 cell line and the status of the rDNA within the host is as follows. Briefly, a total of 1.5 ⁇ 10 e7 cells were transfected with 1.8 ug of linearized plasmid DNA together with 15 ul of FreeStyle MAX Reagent (Invitrogen) in a volume of 30 ml. The transfected cell cultures were incubated at 37 C, 8% CO2 on an orbital shaker platform.
- the cells were cultured in hypoxanthne- and thymidine-deficient, medium supplemented with Gentamycin at a final concentration of 500 ug/ml for selection of uptake of plasmid DNA.
- Clones were selected by limiting dilution cloning. Several single clones arising from a single cell were expanded and cell lines were characterised for production of human growth hormone. Resulting clones were examined for growth properties in comparison to the standard CHO DG44 cell line.
- Linearized plasmid pNeuMAB DNA encoding Infliximab genes was used to transfect NeuCHO cell cultures At 48 hours post transfection the cells were cultured into hypoxanthne- and thymidine-deficient, medium to select for cells expressing the DHFR gene. A stable cell population was then subjected to subsequent stepwize increasing methotrexate (MTX) concentration (50-, 100-, 200-, 400-, 800 nM, 1 uM) in order to amplifiy template DNA copy number and gene expression. Clones were selected by limiting dilution cloning. Clones with high level expression of infliximab protein were scaled up for protein production.
- MTX methotrexate
- a critical part of quality control involves the full characterization of cells.
- the cell banks are examined for adventitious agents (viral, bacterial, fungal and mycoplasmal). Documentation describing the type of banking system used, the size of the cell bank(s) the container (vials, ampoules and closure system used, the methods used for preparation of the cell bank(s) including the cryoprotectants and media used, and the conditions employed for cryopreservation and storage are provides.
- gene gene gene DHFR gene Auxotrophic Auxotrophic Auxotrophic selection in HT selection in HT selection in HT negative media negative media negative media eliminates the eliminates the eliminates the need to maintain need to maintain need to maintain selection selection selection pressure using pressure using pressure using antibiotics. antibiotics. antibiotics. antibiotics. Amplification of Amplification of Amplification of gene copy gene copy gene copy number is number is number is accomplished by accomplished by accomplished by the addition the addition the addition of of methotrexate to of methotrexate to methotrexate to the culture the culture the culture media. The media. The media.
- the murine DHFR murine DHFR murine DHFR gene is driven gene is driven gene is driven gene is driven by a minimal by a minimal by a minimal SV40 early SV40 early SV40 early promoter promoter promoter lacking the lacking the lacking the enhancer enhancer enhancer sequence. sequence. sequence Ampicillin For propagation For propagation For propagation For propagation resistance of plasmid in of plasmid in of plasmid in of plasmid in gene bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria bacteria Neomycin For selection in gene mammalian cells
- the intron sequence II The intron sequence II sequence from rabbit beta from rabbit beta from rabbit beta globin gene is located globin gene is located globin gene is located globin gene is located downstream of the downstream of the downstream of the promoter providing promoter providing promoter providing for increased for increased for increased expression and mRNA expression and mRNA expression and mRNA stability of the stability of the stability of the transcription unit transcription unit transcription unit Intenal Ribosome
- IVS Entry Site
- recombinant gene recombinant gene. recombinant gene. DHFR gene Auxotrophic selection Auxotrophic selection Auxotrophic selection in HT negative media in HT negative media in HT negative media eliminates the need to eliminates the need to eliminates the need to maintain selection maintain selection maintain selection pressure using pressure using pressure using antibiotics. antibiotics. antibiotics. antibiotics. Amplification of gene Amplification of gene Amplification of gene copy number is copy number is copy number is accomplished by the accomplished by the accomplished by the addition of addition of addition of methotrexate to the methotrexate to the methotrexate to the culture media. The culture media. The culture media. The culture media.
- the murine DHFR gene is murine DHFR gene is murine DHFR gene is driven by a minimal driven by a minimal driven by a minimal SV40 early promoter SV40 early promoter SV40 early promoter lacking the enhancer lacking the enhancer lacking the enhancer lacking the enhancer sequence. sequence. sequence. Ampicillin For propagation of For propagation of For propagation of resistance gene plasmid in bacteria plasmid in bacteria plasmid in bacteria Neomycin gene
- FIG. 1 A-H depicts a series of expression vector map relevant to expression using CHO DG44 cell lines or NeuCHO cell lines.
- FIG. 1A depicts an expression vector pNAS including hGH coding sequence for use in constructing the NeuCHO Cell Line from CHO DG44.
- NeuCHO cell line is produced by the inclusion of the vector shown in FIG. 1A within a CHO-DG44 cell line.
- the genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 1.
- CHO DG44 cell line includes a relatively and fragile cell line which inherently has issues and problems in regard to long term viability, cell density and population stability.
- the addition of hGH to the cell culture vector may lead to increases in cell density or production that were previously not realisable using previous techniques and sequences.
- growth factors such as IGF-1 and insulin were used to supplement CHO cells (such as DG44).
- DG44 CHO cells
- these previous methods lead to disappointing results in terms of cell viability and/or survival.
- the addition of hGH coding sequences to CHO cells allows for the excretions by the CHO-DG44 cells of hGH. This expression and secretion of hGH into the cell media leads to increase in cell survival of CHO cells.
- hGH may also improve the robustness of the NeuCHO cell line as compared to other CHO cell lines.
- the NeuCHO cell line may include any of the expression vectors described and shown in respect to FIGS. 1 A-H.
- the CHO-DG44 cell line was transfected with the pNAS-hGH vector to produce the NeuCHO cell line.
- Possible transfection methods include: standard methods described in the scientific literature including: calcium phosphate precipitation, PEI, Electroporation and lipofaction. It is generally noted that previous teachings in the field have often argued that it is preferred to deliver higher relative levels of DNA to cells by transfection to get better results. However, transfection methods delivering more DNA into the cell do not generate more stable or high producing cell lines, as the cell lines may become less stable and less robust.
- FIG. 1B depicts an expression vector used for the expression of a single chain protein in CHO DG44 cells.
- the recombinant gene expression may be driven by the SV40 early promoter/enhancer within the vector.
- the genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 2.
- FIG. 1C depicts an expression vector used for the expression of a single chain protein in CHO DG44 cells.
- a dicistronic expression cassette with a recombinant gene in the 1 st cistron followed by a DHFR gene in the 2 nd cistron is described in this example.
- the gene expression in this vector is preferably driven by SV40 early promoter or enhancer.
- the genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 3.
- FIG. 1D depicts a pNeuMAB, which is a dual expression vector containing two cloning cassettes to insert heavy and light chain genes into a single vector.
- This expression vector has two gene expression cassettes for the insertion of multiple recombinant genes. Each cassette includes an SV40 early promoter and downstream poly A sequence. Each gene is driven by driven SV40 promoter without an enhancer sequence.
- This expression vector is suitable for expression of light and heavy chains expression of the antibodies.
- the genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 4.
- FIG. 1E depicts a further expression vector, pNeuMAB-IRES-DHFR, for high level expression of heavy and light chains of a recombinant monoclonal antibody on a single vector driven one SV40 promoter and enhancer.
- This expression vector may be used for the expression of light and heavy antibody chains.
- This expression vector generally includes two gene expression cassettes for insertion of recombinant genes. Each cassette consists of SV40 early promoter/enhancer and downstream poly A sequence. Heavy chain and light chain are inserted in 1st and 2nd cassettes respectively. The 2nd cassette is dicistronic having light chain followed by DHFR downstream of IRES.
- SEQ. ID No. 5 The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 5.
- FIG. 1F depicts a further expression vector, pNeuMAB-IRES-DHFR-(CMV), for high level expression of heavy and light chains of recombinant monoclonal antibody on a single vector driven by CMV and SV40 promoters of heavy and light chains of antibodies respectively.
- the DHFR gene is driven by IRES downstream of light gene; for the expression of heavy and light chains of antibody in opposite orientations with respect to each other. Heavy chain is driven by CMV promoter whereas light chain is driven by SV40 promoter/enhancer. Light chain and DHFR gene have a dicistronic configuration with DHFR downstream of IRES.
- the genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 6.
- FIG. 1G depicts a further expression vector, pMAB-LC (ires-dhfr), for expression of only light chains (LC) of antibodies.
- pMAB-LC ires-dhfr
- the vector is used in co-transfection with pMAB HC, which is the expression vector shown in FIG. 1H .
- the genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 7.
- FIG. 1H depicts a further expression vector, pMAB-HC, for expression of only heavy chain (HC) of antibodies. Both pMAB-LC and pMAb-HC are co-transfected for expression of complete antibody.
- the genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 8.
- FIG. 2 A further graph is shown in FIG. 2 .
- the graph of FIG. 2 represents the: Growth of DG44 Cell Lines expressing IGF-1 or hGH compared to the Parental DG44 Cell Line and a Mock Cell Line.
- a control (mock) cell line is derived from the Parental Cell Line which has been stably transfected with a DNA plasmid containing the selection marker but without the Gene Of Interest (GOI).
- the preferred NeuCHO Cell Line demonstrates superior growth advantage compared to the original Parental DG44 Cell Line.
- the growth of NeuCHO cells demonstrates higher viable cell densities to that of a DG44 Cell Line expressing the IGF-1 gene.
- This graph shows that when DG44 cells express human Growth Hormone, (Line Graphs E and F), the cells have a very high Maximum Viable Cell Density (up to 425%) compared to the untransfected DG44 Parental Cell Line, the Mock transfected Cell Line, and DG44 Cell Lines expressing high or Low IGF-1 protein.
- the NeuCHO Cell Line has an Integral Cell Density of up to 3.67 ⁇ 10 7 cell/day/mL, which is 230% that of the Parental DG44 Cell Line, 1.57 ⁇ 10 7 cell/day/mL.
- the Viable Cell Density is plotted on the Y-axis in cells/mL, and the number of days in culture is plotted on the X-axis.
- Six line graphs are shown in the figure, namely line graph A, B, C, D, E and F.
- Line A represents the growth pattern of a parental DG44 cell line that is not transfected with DNA.
- Line B represents the growth pattern of a parental DG44 cell line that was transfected with a DNA plasmid containing the selection marker but without the Gene Of Interest (GOI).
- GOI Gene Of Interest
- Line C represents the growth pattern of a parental DG44 cell line that was stably transfected with a DNA plasmid containing both the selection marker and the Gene Of Interest (GOI).
- the GOI here is Insulin-like growth factor 1 (IGF-1).
- Line D represents the growth pattern of a parental DG44 cell line that was stably transfected with a DNA plasmid containing both the selection marker and the Gene Of Interest (GOI).
- the GOI here is Insulin-like growth factor 1 (IGF-1).
- Line E represents the growth pattern of a parental DG44 cell line that was stably transfected with a DNA plasmid containing both the selection marker and the Gene Of Interest (GOI).
- the GOI here is human Growth Hormone (hGH).
- Line F represents the growth pattern of a parental DG44 cell line that was stably transfected with a DNA plasmid containing both the selection marker and the Gene Of Interest (GOI).
- the preferred GOI in this example is human Growth Hormone (hGH).
- FIG. 3 a further graph is depicted comparing the integral of viable cell densities (IVCD) of NeuCHO with the standard CHO DG44 cells. This figure demonstrates the difference in the Integral of Viable Cell Densities achieved with the parent cell line NeuCHO compared to parental CHO.
- IVCD integral of viable cell densities
- the NeuCHO cell line is superior in growth capabilities and this translates into a more efficient production process which can minimize costs by having higher productions rates, fewer production runs, thus lower productions costs, lower Cost of Goods (COGS).
- the preferred NeuCHO cell line demonstrates high titre of mAB x compared to traditional CHO expression system.
- FIG. 5 demonstrates in graphical form that NeuCHO cells may have greater stable transfection efficiency than CHO cells (such CHO DG44 cells).
- Cells (NeuCHO and CHO) were transfected with DNA encoding mAB ‘x’ prior to selection and single cell cloning from a stable pool.
- the data is shown in FIG. 5 and demonstrates that stable transfection of NeuCHO cells results in a greater number of clones with high productivity than that of standard CHO cells.
- the graph shows the levels of various protein expressed in relative quantities at a given time.
- NeuCHO cells have an integral of viable cell density that is about 230% greater than CHO DG44 cell lines.
- CHO DG44 cell lines expressing insulin like growth factor 1 (IGF-1) do not demonstrate the ability to grow to high cell densities as NeuCHO cell lines may generally achieved.
- NeuCHO cells have a generally greater transfection efficiency than CHO DG44 cells.
- the survival rate of transfected NeuCHO cells is generally greater then transfected CHO DG44 cells. Additionally, transfection of NeuCHO cells may result in a greater number of clones with a higher productivity than that of standard CHO DG44 cells.
- the expression system and vectors described herein may be able to allow or facilitate CHO cells such NeuCHO or CHO DG44 cells to produce desired proteins suitable for pharmaceutical preparation including, but not limited to: Infliximab tumour necrosis factor (referred to as RemicabTM); Adalimumab tumour necrosis factor (referred to as HumiraTM); Etanercept tumour necrosis factor (referred to as EnbrelTM); Rituximab CD20 (referred to as RituxanTM & MabTheraTM); Bevacizumab vascular endothelial growth factor (referred to as AvastinTM); Trastuzumab HER2 (referred to as HerceptinTM); Ranibizumab vascular endothelial growth factor (referred to as Lucentism); Cetuximab epidermal growth factor receptor (referred as ErbituxTM); Erythropoietin a; Interferon ⁇ -Pegylated interferon alfa-2a; Interferon ⁇
- NeuCHO cells when used as feeder layer may also increase efficiency of single cell cloning.
- NeuCHO cells were seeded in single wells of microtitre plates prior to single cell cloning of a stable transfected pool. Secretion of human growth hormone secreted from NeuCHO cells results in an increased survival rate of single cells following Limiting Dilution Cloning.
- the present invention and the described preferred embodiments specifically include at least one feature that is industrial applicable.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- The present invention relates to expression systems, in particular the invention relates to expression systems for the production of biological therapeutics.
- Expression systems for the production of biological therapeutics or biopharmaceuticals, such as recombinant proteins, generally consist of a nucleic acid vector construct encoding the desired recombinant therapeutic and a chosen host cell. The vector is introduced into the host cell and the endogenous cell machinery is utilised for the production of the desired therapeutic i.e. the desired recombinant protein. The intricacies in establishing an efficient and reliable expression system for the production of approvable biological therapeutics are manifold. However, well-established expression systems may provide cost-effective alternatives for the production of pharmaceutical products otherwise difficult to obtain.
- Efficiency of the system itself depends on a large variety of factors including the design of the vector and the choice of host cell. The strategic combination of regulatory elements, selection markers and stability elements within the vector sequence have to balance simple manipulation and application of the vector with high yield production of the desired biological therapeutic. Determining a cell's suitability to act as host cell in such an expression system is primarily governed by the need to maximise compatibility between the endogenous cell machinery and the regulatory elements present in the vector, while keeping potential adventitious contaminants in the final product minimal. Further, availability, cost and acceptability for regulatory approval of any therapeutic produced by the system, have to be considered.
- Nucleic acid vectors used in expression systems comprise plasmids, cosmids, Yeast Artificial Chromosomes (YACs), Bacterial Artificial Chromosomes (BACs), retroviral, adenoviral and lentiviral vectors. These vectors differ in many characteristics, such as their capacity to accommodate different sized nucleic acid inserts, their most efficient introduction method into the host cell and specifically in their utilisation of the endogenous cell machineries of different types of host cells to ensure sufficient expression of the desired protein.
- Regulatory elements commonly present in such expression vectors influence transcription, translation as well as protein synthesis of selection markers and of sequences encoding the desired biological therapeutic. Such regulatory elements include, but are not limited to, promoters, terminators, modifiers, insulators, spacers, regulatory protein binding sites, introns, inducers, etc.
- Known promoters include constitutively active promoters such as the thymidine kinase (TK) promoter, the actin promoter, the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter, the simian vacuolating virus 40 (SV40) early promoter, the cyclin T1 promoter, the RNA polymerase III U3 promoter, the cyclophillin promoter, the cytomegalovirus (CMV) promoter, the Autographa californica nuclear polyhedrosis virus (AcNPV) P10 promoter and the β3-galactosyltransferase 5 (β3GAL-T5) promoter.
- Known promoters also include inducible promoters such as the heat shock protein 70 (HSP70) promoter (stress induced), the heat shock protein 90 (HSP90) promoter (stress induced), the alcoholdehydrogenase I (alcA) promoter (alcohol induced), the activating copper-metallothionein expression (ACEl) promoter (metal induced), the small subunit of ribulose-1,5-bisphophate-carboxylase (SSU1) promoter (light induced), the hypoxia induced factor 1α (hif1α) promoter (hypoxia induced), the inducer of meiosis 2 (IME2) promoter (starvation induced), the glucocorticoid receptor (hormone induced), the estrogen receptor (hormone induced) and the ecdysone receptor (hormone induced).
- Further, cell type/tissue specific promoters, such as the nkx2.5 promoter (heart cells), the
islet 1 promoter (pancreatic cells), the MyoD promoter (muscle cells), the cluster of differentiation 2 (CD2) promoter (T-cells) and the collagen II promoter (cartilage), are known to change their level of activity in response to cell type specific stimuli or to progression through developmental stages. - Known terminator elements, such as the RNA Polymerase II terminator, the small nucleolar RNA 13 (snR13) terminator, the bovine growth hormone (BGH) terminator, the simian virus 40 (SV 40) terminator and the thymidine kinase (TK) terminator, may provide suitable polyadenylation signals.
- Known modifier and insulator elements include the tetracycline operator/receptor (tetO/tetR) system, the upstream activating sequence of the galactose dependent GAL4 transcription factor (GAL4 UAS), the adenovirus early region B1 TATA box, binding sites for the herpes simplex virus (HSV) regulatory protein VP16, the 5′HS4 chicken β-globin insulator, the paternally expressed gene 3 (Peg3) insulator and the sea urchin arylsulfatase (ARS) gene insulator.
- While many attempts have been made to establish efficient and reliable expression systems for the production of approvable biological therapeutics, problems relating to low yield and adventitious contamination of the produced biopharmaceuticals remain. Choosing the most effective combination of suitable regulatory elements from the plethora of options, such that the system conveys stability and the highest degree of compatibility with the endogenous host cell machinery, poses a major challenge in the field.
- Obtaining regulatory approval for a biopharmaceutical product poses a further challenge. Regulatory approval involves determination of the safety and efficacy of the pharmaceutical product prior to marketing. The process of gaining regulatory approval for innovator drugs is very time consuming and expensive. However, once approved, these drugs may be very profitable, particularly when they are marketed under exclusivity rights such as patent protection.
- The profitability of innovator drug's market may provide a substantial incentive to exploit this market once patent rights have expired. Following patent expiry, innovator drugs can be marketed as generic drugs or biosimilars for drugs produced by recombinant DNA technology. Generic versions of blockbuster biopharmaceuticals near patent expiry include Epogen (erythropoietin, EPO) and Neupogen (granulocyte colony stimulating factor, G-CSF). The approval of a follow-on version of Pfizer's Genotropin (recombinant human growth hormone) seems to indicate a change in a landscape where previously, biopharmaceuticals enjoyed immunity from competition even after expiration of their patent protection. At present, there are over 80 generic versions of biopharmaceuticals in development (Datamonitor 2010).
- Biosimilars ideally are bioequivalents of the innovator drugs and, as such, the path to regulatory approval for biosimilars is in theory less arduous than for the original innovator drug as the clinical data establishing safety and efficacy have been carried out.
- Approval of generic biopharmaceuticals is dependent on comparable dosage form, strength, route of administration, quality, performance characteristics and intended use compared with approved biopharmaceuticals (that is, the reference listed drugs). For example, under the United States Food and Drug Administration (FDA), approval for a generic drug involves an “Abbreviated New Drug Application” (ANDA) which generally does not include pre-clinical and clinical data to establish safety and effectiveness. Approval also involves a bioequivalence review, which establishes that the proposed generic drug is bioequivalent to the reference-listed drug. This bioequivalency is based upon a demonstration that the rate and extent of absorption of the active ingredient in the generic drug fall within the scope of the parameter of the reference listed drug.
- Importantly, there is a chemistry/microbiology review process that provides an assurance that the generic drug will be manufactured in a reproducible manner under controlled conditions to ensure that the drug will perform in a safe and acceptable manner.
- Although guidelines for the approval of biosimilar drugs exist, there is uncertainty in regard to the practicalities of regulatory approval of biosimilars. Much of the uncertainty is driven by the lack of a clear practical and detailed regulatory pathway for the approval of such drugs and the scientific debate over product comparability and interchangeability. The uncertainties resulting from the manufacture of biosimilar drugs under conditions different than those used by the innovator suggest that it may be impossible to develop a true “generic” version of a biotechnology drug. Indeed, regulatory authorities in Europe and the US have shunned the use of the term “biogeneric”, preferring the nomenclature “biosimilar” and “follow-on biologicals”.
- Many quality concerns for expression system-derived biopharmaceuticals have originated from the presence of adventitious contaminants or from the properties of the host cells used to prepare the product. Several of these products have also had quality concerns regarding the expression vector of the system. It is well established that cell properties and events linked to cell culture can affect resultant product quality and safety. Effective quality control of recombinant products requires appropriate controls on all aspects of handling the cell and cell culture. This is particularly relevant to the development of biosimilars.
- Previously, Chinese Hamster Ovary (CHO) cells were modified and engineered to produce insulin. However these CHO cells were unable to express biological active insulin and thus the patents associated with this type or method of CHO cell modification were not commercial exploited. Fully functional insulin was not produced in CHO cells due to cryptic splicing of the insulin gene message by the translational machinery In the CHO cell.
- Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
- It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.
- A first aspect of the present invention may relates to novel expression systems and methods of employing an expression system according to the invention that may, in certain embodiments, increase the yield and decrease the cost of manufacture.
- This invention relates to methods of production of recombinant biosimilars, bio-pharmaceuticals and other desirable proteins, polypeptides and peptides using mammalian cell cultures. In particular, the methods of the invention involve the use of specially bioengineered mammalian cell lines for the production of complex proteins in low cost media. These cell lines have the acquired ability for autonomous growth in cheap, reproducible, fully-defined protein-free medium, with the cells expressing and secreting its growth factor requirements.
- Accordingly, in a first aspect, the present invention provides an expression system for expressing a protein comprising:
- a eukaryotic host cell carrying a dihydrofolate reductase (DHFR) deficiency an expression vector, the expression vector encoding the human growth hormone gene;
an expression vector, the expression vector comprising:
a eukaryotic selectable marker downstream of for expression of a sequence encoding dihydrofolate reductase for complementing the DHFR deficiency in the host cell; a prokaryotic selectable marker conveying Ampicillin resistance to a prokaryotic host cell;
a prokaryotic Origin of Replication
a plurality of multiple cloning sites (MCS); and
at least one protein expression module comprising:
a Simian Vacuolating Virus 40 (SV40) early promoter, inclusive of its 72 bp enhancer repeats; and a rabbit β-globin intron sequence being separable from a SV40 polyadenylation sequence by a first multiple cloning site, for receiving a coding sequence and expressing a desired protein therefrom. - Preferably, the expression system further comprises a second protein expression module, the second protein expression module including: a Cyotomegalovirus promoter being separable from a SV40 polyadenylation sequence by a second multiple cloning site for co-expression of at least two proteins from the expression modules.
- Preferably, the protein is the subject of a request for regulatory approval and wherein the host cell is subjected to a plurality of predetermined manipulations such that the host cell expresses said protein; and wherein information is recorded on each manipulation and each manipulation is carried out in a manner which prevents contact of the host cell with a contaminating agent; and wherein the information is used to generate a history record of the host cell for inclusion in a submission to a regulatory agency involved in assessing the safety and efficacy of drugs thereby expediting regulatory approval of the protein.
- The predetermined manipulations preferably comprise:
-
- (i) ligating the coding sequence encoding the desired protein into the expression vector to produce a recombinant vector;
- (ii) introducing the recombinant vector into the host cell; and
- (iii) culturing the host cell under conditions such that the protein is expressed by the host cell.
- Preferably the recombinant vector is at least in part incorporated into the genome of the host cell. Step (iii) includes growing the host cell in a medium that contains no animal or plant derived proteins or peptides and no undefined hydolysates or lysates thereby reducing contact of the host cell with a contaminating agent.
- In a particularly preferred embodiment, the host cell is a Chinese Hamster Ovary (CHO) DG44 cell.
- In certain preferred embodiments, the host CHO DG44 expresses a growth hormone. In certain preferred embodiment the growth hormone is human growth hormone. In certain preferred embodiments, the protein may be a biosimilar drug.
- In a second aspect, the present invention provides a method of managing the development of a protein expressed by the expression system according to the first aspect wherein the protein is the subject of a request for regulatory approval, the method comprising the steps of:
-
- a. subjecting the host cell to a plurality of predetermined manipulations such that the cell expresses the protein;
- b. recording information on each manipulation wherein each manipulation is carried out in a manner which prevents contact of the host cell with a contaminating agent;
- c. using the information to generate a history record of the host cell for inclusion in a submission to a regulatory agency involved in assessing the safety and efficacy of drugs; and
- d. including the history record in the submission to the regulatory agency for regulatory approval of the product.
- In a third aspect, the present invention provides a method of expediting regulatory approval of a protein expressed by the expression system according to the first aspect the method comprising:
-
- b. subjecting the host cell to a plurality of predetermined manipulations such that the host cell expresses the product;
- c. recording information on each manipulation wherein each manipulation is carried out in a manner which prevents contact of the host cell with a contaminating agent;
- d. using the information to generate a history record of the host cell for inclusion in a submission to a regulatory agency involved in assessing the safety and efficacy of drugs; and
- e. including the history record in the submission to the regulatory agency for regulatory approval of the protein.
- Preferably, step (a) of the methods according to the second and third aspect comprises
-
- (i) ligating the coding sequence encoding the desired protein into the expression vector to produce a recombinant vector;
- (ii) introducing the recombinant vector into the host cell; and
- (iii) culturing the host cell under conditions such that the protein is expressed by the host cell.
- The recombinant vector is preferably at least in part incorporated into the genome of the host cell.
- Preferably, step (iii) of the methods according to the second and third aspect includes growing the host cell in a medium that contains no animal or plant derived proteins or peptides and no undefined hydrolysates or lysates thereby reducing contact of the host cell with a contaminating agent.
- In a particularly preferred embodiment of the methods according to the second and third aspect, the protein is a biosimilar drug.
- Another aspect of the present invention may also provide a method for producing a desired recombinant protein, polypeptide or peptide comprising the step of: culturing a mammalian host cell in culture medium, wherein said host cell includes:
- (i) at least one introduced DNA sequence encoding a protein, polypeptide and/or peptide factor(s) required for growth of the host cell in said culture medium, expressibly linked to a constitutive promoter (e.g. CMV and SV40 promoters) The invention thereby enables the use of low cost, protein/serum-free medium by utilising a host cell which is able to produce the protein, polypeptide and/or peptide growth factor(s) required for its growth in such medium. The culture medium used in the method of the invention is, therefore, preferably serum-free or otherwise free of protein, polypeptide and/or peptide growth factor(s) necessary for the growth of the particular host cell type. However, methods wherein the culture medium includes one or more of the required growth factor(s) and the host cell itself expresses one or more of the same and/or other required growth factor(s), is also to be regarded as falling within the scope of the invention.
- The mammalian host cell may be any of those commonly used in the art for expressing recombinant proteins, polypeptides or peptides. For example, the host cell may be a Chinese Hamster Ovary (CHO) cell such as CHO-K1, CHO-DG44 DHFR- and CHO-S. These include both adherent and suspension cell lines. Also other cell lines described within the embodiments of the present invention may also be used or preferred.
- The introduced DNA sequence(s) may be present on plasmids or otherwise integrated into the host cell chromosomes (e.g. by homologous recombination).
- The DNA sequence(s) encoding the protein, polypeptide and/or peptide factor(s) required for growth of the host cell, may be selected from DNA sequences encoding human Growth Hormone (hGH), modified hGH and other growth factors and mixtures thereof. Where the host cell is CHO it is preferable that the host cell includes DNA sequences encoding human Growth Hormone (hGH).
- In the context of the present invention, the words “comprise”, “comprising” and the like are to be construed in their inclusive, as opposed to their exclusive, sense, that is in the sense of “including, but not limited to”.
- In the context of the present invention, the words “comprise”, “comprising” and the like are to be construed in their inclusive, as opposed to their exclusive, sense, that is in the sense of “including, but not limited to”.
- The invention is to be interpreted with reference to the at least one of the technical problems described or affiliated with the background art. The present aims to solve or ameliorate at least one of the technical problems and this may result in one or more advantageous effects as defined by this specification and described in detail with reference to the preferred embodiments of the present invention.
-
FIG. 1A is a plasmid vector map entitled “pNAS-hGH” for the high level expression human growth hormone (hGH) inserted within a pNAS vector with use with NeuCHO cell line; -
FIG. 1B is an expression vector map entitled “pNeu” used for the high level expression of a single chain protein in CHO DG44 cells; -
FIG. 1C is an expression vector map entitled “pNeu-IRES-DHFR” used for the high level expression of a single chain protein in CHO DG44 cells. A dicistronic expression cassette with recombinant gene in 1st cistron followed by DHFR gene in 2nd cistron; -
FIG. 1D is an expression vector map entitled “pNeuMAB” used for the high level expression of heavy and light antibody chains and/or recombinant monoclonal antibodies; -
FIG. 1E is an expression vector map entitled “pNeuMAB-IRES-DHFR” used for the high level expression of heavy and light antibody chains; -
FIG. 1F is an expression vector map entitled “pNeuMAB-IRES-DHFR (CMV)” used for the high level expression of heavy and light antibody chains; -
FIG. 1G is a single chain expression vector map entitled “pMAB LC (IRES-DHFR)” used for expression of light chains (LC); -
FIG. 1H is a single chain expression vector map entitled “pMAB HC” used for expression of heavy chains (HC); -
FIG. 2 . depicts a growth chart demonstrating viable cell density plotted against time in respect of various cultures and cells used. Growth of DG44 Cell Lines expressing hGH compared to the Parental DG44 Cell Line and a DG44 Cell Line expressing the IGF-1 gene; -
FIG. 3 . depicts a graph comparing the integral of viable cell densities against time for various preferred organisms and culture; and -
FIG. 4 . depicts a comparison chart showing the relative expression levels of proteins from either CHO DG44 cells or NeuCHO cell lines. - This specification also includes the following genetic sequence information relating to expression vectors:
- Sequence No. 1 depicts the preferred coding sequence for the expression vector pMAB HC;
- Sequence No. 2 depicts the preferred coding sequence for the expression vector pMAB LC(ires-dhfr);
- Sequence No. 3 depicts the preferred coding sequence for the expression vector pNAS-hGH;
- Sequence No. 4 depicts the preferred coding sequence for the expression vector pNeu;
- Sequence No. 5 depicts the preferred coding sequence for the expression vector pNeu-IRES-DHFR;
- Sequence No. 6 depicts the preferred coding sequence for the expression vector pNeuMAB;
- Sequence No. 7 depicts the preferred coding sequence for the expression vector pNeuMAB-IRES-DHFR (CMV);
-
Sequence 8 depicts the preferred coding sequence for the expression vector pNeuMAB-IRES-DHFR; - Please note that in this specification Sequence No. is same and the equivalent term to SEQ ID NO.
- Preferred embodiments of the invention will now be described with reference to the accompanying drawings and non-limiting examples.
- It has been found that events during the culture of a cell may contribute significantly to the assessment of the risks associated with the use of that particular cell for production of proteins and more particularly proteins for therapeutic use.
- Diligent records of all manipulations including the history of a cell throughout development, extending to the parental cell line from which it was derived, may contribute to the quality and safety of the final product.
- In one scenario, such information may be important for gaining regulatory approval of protein therapeutics expressed from a cell. In particular, biosimilars present unique issues. These issues include demonstrating that immunogenicity of the biosimilar has not been altered with respect to the reference listed drug, as well as ensuring that there are no undetected differences in the product that may potentially impact the safety and efficacy of the drug. Resolving such issues would be problematic without conducting extensive clinical trials. As such, it is likely that any application for a biosimilar would be required to demonstrate that there are no clinically meaningful differences in safety, purity and potency between the biosimilar and the reference listed drug. Moreover, an application for a biosimilar would need to provide evidence that the biosimilar has “profound similarity” (as it is impractical to demonstrate identical biological products) and that the biosimilar will produce the same clinical result as the reference listed drug in any given patient.
- In order to gain regulatory approval, traditional generic manufacturers are required to demonstrate their drug is chemically identical to the referenced listed drug and exhibit the same properties in the human body as the original drug. In regard to biosimilars, it was previously not possible to readily demonstrate that a second-source biologic drug is unequivocally identical to an innovator drug due to the complexities of the synthesis of the drugs in potentially disparate biological systems. As such, biosimilars may exhibit slightly different properties to the original drugs that may necessitate abbreviated clinical trials in order to gain regulatory approval.
- In the context of the present invention, the term “contaminating agent” refers to any agent that can potentially compromise regulatory approval of a product by a regulatory agency. Such agents may include but are not limited to adventitious agents such as viruses, bacteria, fungi and mycoplasma or proteins there from.
- As used herein the term “cell expressed product” refers to any product produced by the cell, including but not limited to proteins, peptides, glycoproteins, carbohydrates, lipids, glycolipids and nucleic acids.
- The term “regulatory approval” in so far as it relates to a product defined in the context of this specification, refers to approval from a regulatory authority which permits marketing of the product.
- The term “safety and effectiveness studies” refers to any studies conducted on a product that assess the safety and efficacy of that product for human and/or animal administration.
- The term “clinical trials” refers to studies involving either animal or humans designed assess the safety and/or efficacy of a product for a therapeutic application.
- The term “abbreviated safety effectiveness studies and/or abbreviated clinical trials” refers to studies carried out on a drug which does not involve complete phase I, II and III clinical trials. Such studies may include a bioequivalence review and a chemistry/microbiology review as defined by the US Food and Drug Administration (FDA).
- The term “biosimilar drug” and ‘biosimilar” refer to a bioequivalent pharmaceutical of a drug in which patent protection has expired and where the previously protected drug has regulatory approval. In particular, this includes products prepared in cell culture by recombinant DNA technology. The term “biosimilar drug” and ‘biosimilar” as used herein is equivalent to the terms “follow-on biologicals” or “biosimilars”.
- The term “protein” refers to a “complete” protein as well as fragments, derivatives or homologs or chimeras thereof comprising one or more amino acid additions, deletions or substitutions, but which substantially retain the biological activity of the complete protein.
- The embodiments of the present invention will now be described by reference to the following non-limiting examples.
- Construction of pNeu and pNAS Vectors for High Level Expression of Recombinant Therapeutic Protein
- The vector pNeu was designed for high-level expression of single chain peptides for the production of therapeutic proteins. The vector facilitates the insertion DNA sequences into a convenient multiple cloning site for expression in CHO cells. See Table 1 and
FIG. 1A for a description of the vector and its component features. - The 5026 bp vector encodes essential coding and regulatory sequences for the efficient expression of the recombinant gene as well as essential sequences for the selection and propagation of the plasmid in bacteria. It was designed for chemical synthesis and is void of nonessential and redundant sequences that are common components in commercial expression vectors. This allows for ease of genomic insertion with less likelihood of deletion of sequences during plasmid propagation resulting in loss of expression. The multiple cloning site encodes a minimum of two unique restriction sites for rapid gene cloning.
- Synthesis and Cloning of Human Growth Hormone (hGH) cDNA into pNAS
- The amino acid sequence encoding for hGH was subjected to bioinformatic analysis through proprietary third party software by GENEART AG, Regensburg Germany. Codon options were utilized to maximize expression by improving mRNA maintenance and the exploitation of available tRNA pools in CHO cells. RNA and codon optimization was performed on the coding sequences. The gene was analysed with respect to splice site recognition, mRNA stability, presence of ribosomal entry sites, mRNA secondary structures, self-homology for the purpose of increasing gene expression in CHO cells. The hGH gene was cloned into pNAS using AgeI and EcoRV restriction sites using methods well known in the art.
- Construction of pNeuMAB Vector for Expression of Recombinant Monoclonal Antibody
- The pNeuMAB vector was designed for the cloning and expression of recombinant monoclonal antibodies. The DNA encoding heavy and light chains are configured in the vector as two distinct and tandem transcription units. See Table 1 and
FIG. 1B for a description of the vector and its component features. - Synthesis of cDNA Encoding Heavy Chain and Light Chain of an Antibody-Infliximab
- The amino acid sequence encoding the heavy chain (HC) and light chain (LC) of the monoclonal antibody, Infliximab were subjected to bioinformatic analysis through proprietary third party software by GENEART AG, Regensburg Germany. Codon options were utilized to maximize expression by improving mRNA maintenance and the exploitation of available tRNA pools in CHO cells. RNA and codon optimization was performed on the coding sequences. The genes were analysed with respect to splice site recognition, mRNA stability, presence of ribosomal entry sites, mRNA secondary structures, self-homology for the purpose of increasing gene expression in CHO cells.
- Cloning Gene Encoding Heavy Chain of Infliximab
- The synthetic gene encoding for the heavy chain of Infliximab was assembled from synthetic oligonucleotides and/or PCR products. The fragment was cloned into pGA14 (ampR) using AscI and PacI restriction sites. The plasmid DNA was purified (Pure Yield™ Plasmid Midiprep, Promega) from transformed bacteria and concentration determined by UV spectroscopy. The final construct was verified by sequencing. The sequence congruence within the used restriction sites was 100%. The synthetic cDNA sequence encoding heavy chain of Infliximab was designed to incorporate unique restriction sites Age I and Eco RV at the 5′ and 3′ ends respectively for directional cloning into the first multiple cloning site of NeuClone's antibody expression vector, pNeuMAB digested with the same restriction sites.
- Cloning Gene Encoding Light Chain of Infliximab
- The synthetic gene encoding the light chain of Infliximab was assembled from synthetic oligonucleotides and/or PCR products. The fragment was cloned into pGA18 (ampR) using AscI and PacI restriction sites. The plasmid DNA was purified (Pure Yield™ Plasmid Midiprep, Promega) from transformed bacteria and concentration determined by UV spectroscopy. The final construct was verified by sequencing. The sequence congruence within the used restriction sites was 100%. The synthetic cDNA sequence encoding light chain of Infliximab incorporates the unique restriction sites Sal I and Mlu I at the 5′ and 3′ ends respectively for directional cloning into the second multiple cloning site of NeuClone's antibody expression vector, pNeuMAB digested with the same restriction sites.
- Generation of NeuCHO
- Transfection of DG44 Cells with pNAS-hGH
- One of the preferred methods by which the expression vector encoding human growth hormone into the host CHO DG44 cell line and the status of the rDNA within the host (copy number, etc.) is as follows. Briefly, a total of 1.5×10 e7 cells were transfected with 1.8 ug of linearized plasmid DNA together with 15 ul of FreeStyle MAX Reagent (Invitrogen) in a volume of 30 ml. The transfected cell cultures were incubated at 37 C, 8% CO2 on an orbital shaker platform. At 48 hours post transfection the cells were cultured in hypoxanthne- and thymidine-deficient, medium supplemented with Gentamycin at a final concentration of 500 ug/ml for selection of uptake of plasmid DNA. Clones were selected by limiting dilution cloning. Several single clones arising from a single cell were expanded and cell lines were characterised for production of human growth hormone. Resulting clones were examined for growth properties in comparison to the standard CHO DG44 cell line.
- Transfection of NeuCHO with pNeuMAB Encoding Infliximab Genes
- Linearized plasmid pNeuMAB DNA encoding Infliximab genes was used to transfect NeuCHO cell cultures At 48 hours post transfection the cells were cultured into hypoxanthne- and thymidine-deficient, medium to select for cells expressing the DHFR gene. A stable cell population was then subjected to subsequent stepwize increasing methotrexate (MTX) concentration (50-, 100-, 200-, 400-, 800 nM, 1 uM) in order to amplifiy template DNA copy number and gene expression. Clones were selected by limiting dilution cloning. Clones with high level expression of infliximab protein were scaled up for protein production.
- Cell Banking
- A critical part of quality control involves the full characterization of cells. The cell banks are examined for adventitious agents (viral, bacterial, fungal and mycoplasmal). Documentation describing the type of banking system used, the size of the cell bank(s) the container (vials, ampoules and closure system used, the methods used for preparation of the cell bank(s) including the cryoprotectants and media used, and the conditions employed for cryopreservation and storage are provides.
- The procedures used to avoid microbial contamination and cross-contamination by other cell types present in the laboratory, and the procedures that allow the cell bank containers to be traced are all made available. This includes a description of the documentation system as well as that of a labelling system which can withstand the process of preservation, storage, and recovery from storage without loss of labelling information on the container.
- It is essential that production is based on a well-defined master and working cell bank system. During the establishment of the banks no other cell lines are handled simultaneously in the same laboratory suite or by the same persons. The origin, form, storage, use and expected duration at the anticipated rate of use are described in full for all cell banks.
- The following table identifies some of the components and features of the various expression vectors using with either CHO DG44 or NeuCHO cell lines. The data has been divided into three tables for purposes of presentation in this patent specification.
-
TABLE 1 pNeu-IRES- Feature pNeu DHFR pNAS pNeuMAB Multiple cloning One multiple One multiple One multiple Two multiple site cloning site for cloning site for cloning site for cloning sites for insertion of insertion of insertion of insertion of expression unit expression unit expression unit expression units coding for coding for coding for coding for heavy single chain single chain single chain and light chains protein protein protein of a monoclonal antibody Strong The SV40 The SV40 The CMV early The SV40 promoter/enhancer virus early virus early promoter/enhancer virus early combination promoter/enhancer promoter/enhancer drives expression promoter/enhancer of each drives expression transcription of the first and unit 2nd transcription unit Intron/intervening The intron The intron The intron sequence sequence II sequence II sequence II from rabbit from rabbit from rabbit beta globin beta globin beta globin gene is located gene is located gene is located downstream of downstream of downstream of the promoter the promoter the promoter providing for providing for providing for increased increased increased expression and expression and expression and mRNA stability mRNA stability mRNA stability of the of the of the first transcription unit transcription unit transcription unit Intenal Ribosome For the Entry Site (IRES) expression of DHFR gene downstream of 2nd transcription unit ensuring high level expression of 2nd cistron in cells growing in the presence of methotrexate Polyadenylation A strong A strong A strong A strong signal polyadenylation polyadenylation polyadenylation polyadenylation signal from signal from signal from S40 signal from S40 S40 virus for S40 virus for virus for virus is for efficient efficient efficient efficient expression of expression of expression of expression of recombinant recombinant recombinant each recombinant gene. gene. gene gene DHFR gene Auxotrophic Auxotrophic Auxotrophic selection in HT selection in HT selection in HT negative media negative media negative media eliminates the eliminates the eliminates the need to maintain need to maintain need to maintain selection selection selection pressure using pressure using pressure using antibiotics. antibiotics. antibiotics. Amplification of Amplification of Amplification of gene copy gene copy gene copy number is number is number is accomplished by accomplished by accomplished by the addition the addition the addition of of methotrexate to of methotrexate to methotrexate to the culture the culture the culture media. The media. The media. The murine DHFR murine DHFR murine DHFR gene is driven gene is driven gene is driven by a minimal by a minimal by a minimal SV40 early SV40 early SV40 early promoter promoter promoter lacking the lacking the lacking the enhancer enhancer enhancer sequence. sequence. sequence Ampicillin For propagation For propagation For propagation For propagation resistance of plasmid in of plasmid in of plasmid in of plasmid in gene bacteria bacteria bacteria bacteria Neomycin For selection in gene mammalian cells -
TABLE 2 pNeuMAB- pNeuMAB-IRES- pMAB-LC (ires- Features IRES-DHFR DHFR(CMV) dhfr) Multiple cloning Two multiple Two multiple One multiple cloning site cloning sites for cloning sites for site for insertion of insertion of insertion of Light chain gene expression units expression units coding for heavy coding for heavy and light chains of and light chains of a monoclonal a monoclonal antibody antibody Strong The SV40 virus early The SV40 virus early The SV40 virus early promoter/enhancer promoter/enhancer promoter/enhancer promoter/enhancer combination drives expression drives expression drives expression of of the first of the first gene LC gene and 2nd genes and the CMV promoter drives expression of the 2nd gene. Intron/intervening The intron sequence II The intron sequence II The intron sequence II sequence from rabbit beta from rabbit beta from rabbit beta globin gene is located globin gene is located globin gene is located downstream of the downstream of the downstream of the promoter providing promoter providing promoter providing for increased for increased for increased expression and mRNA expression and mRNA expression and mRNA stability of the stability of the stability of the transcription unit transcription unit transcription unit Intenal Ribosome For the expression For the expression For the expression of Entry Site (IRES) of DHFR gene of DHFR gene DHFR gene downstream of 2nd downstream of 2nd downstream of 2nd transcription unit transcription unit transcription unit ensuring high level ensuring high level ensuring high level expression of 2nd expression of 2nd expression of 2nd cistron in cells cistron in cells cistron in cells growing in the growing in the growing in the presence of presence of presence of methotrexate methotrexate methotrexate Polyadenylation A strong A strong A strong signal polyadenylation polyadenylation polyadenylation signal from S40 signal from S40 signal from S40 virus for efficient virus for efficient virus for efficient expression of expression of expression of recombinant gene. recombinant gene. recombinant gene. DHFR gene Auxotrophic selection Auxotrophic selection Auxotrophic selection in HT negative media in HT negative media in HT negative media eliminates the need to eliminates the need to eliminates the need to maintain selection maintain selection maintain selection pressure using pressure using pressure using antibiotics. antibiotics. antibiotics. Amplification of gene Amplification of gene Amplification of gene copy number is copy number is copy number is accomplished by the accomplished by the accomplished by the addition of addition of addition of methotrexate to the methotrexate to the methotrexate to the culture media. The culture media. The culture media. The murine DHFR gene is murine DHFR gene is murine DHFR gene is driven by a minimal driven by a minimal driven by a minimal SV40 early promoter SV40 early promoter SV40 early promoter lacking the enhancer lacking the enhancer lacking the enhancer sequence. sequence. sequence. Ampicillin For propagation of For propagation of For propagation of resistance gene plasmid in bacteria plasmid in bacteria plasmid in bacteria Neomycin gene -
TABLE 3 Features pMAB-HC Multiple cloning site One multiple cloning site for insertion of Heavy chain gene. Vector is similar to pNAS Strong promoter/enhancer The CMV early promoter/enhancer drives combination expression of heavy chain gene Intron/intervening sequence Intenal Ribosome Entry Site (IRES) Polyadenylation signal A strong polyadenylation signal from S40 virus for efficient expression of recombinant gene. DHFR gene Ampicillin resistance gene Neomycin gene For selection in mammalian cells -
FIG. 1 A-H depicts a series of expression vector map relevant to expression using CHO DG44 cell lines or NeuCHO cell lines. - More specifically,
FIG. 1A depicts an expression vector pNAS including hGH coding sequence for use in constructing the NeuCHO Cell Line from CHO DG44. Preferably, NeuCHO cell line is produced by the inclusion of the vector shown inFIG. 1A within a CHO-DG44 cell line. The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 1. - It is noted that CHO DG44 cell line includes a relatively and fragile cell line which inherently has issues and problems in regard to long term viability, cell density and population stability.
- In this preferred embodiment, the addition of hGH to the cell culture vector may lead to increases in cell density or production that were previously not realisable using previous techniques and sequences. Previously, growth factors such as IGF-1 and insulin were used to supplement CHO cells (such as DG44). However these previous methods lead to disappointing results in terms of cell viability and/or survival. In the present embodiments, the addition of hGH coding sequences to CHO cells allows for the excretions by the CHO-DG44 cells of hGH. This expression and secretion of hGH into the cell media leads to increase in cell survival of CHO cells.
- Further the expression of hGH may also improve the robustness of the NeuCHO cell line as compared to other CHO cell lines.
- More specifically, the addition of hGH expressing sequences to CHO-DG44 cells gave rise to a new cell line, NeuCHO cell line. The NeuCHO cell line may include any of the expression vectors described and shown in respect to
FIGS. 1 A-H. - The NeuCho cell line, deposited under the provisions of the Budapest Treaty with the Cell Bank Australia located at 214 Hawkesbury Rd, Westmead, NSW, 2145, Australia as of 4 Feb. 2013 and assigned accession no. CBA20130024, as is particularly suitable for use in pharmaceutical manufacture as described within the present application.
- Preferably, the CHO-DG44 cell line was transfected with the pNAS-hGH vector to produce the NeuCHO cell line. Possible transfection methods include: standard methods described in the scientific literature including: calcium phosphate precipitation, PEI, Electroporation and lipofaction. It is generally noted that previous teachings in the field have often argued that it is preferred to deliver higher relative levels of DNA to cells by transfection to get better results. However, transfection methods delivering more DNA into the cell do not generate more stable or high producing cell lines, as the cell lines may become less stable and less robust.
-
FIG. 1B depicts an expression vector used for the expression of a single chain protein in CHO DG44 cells. Preferably, the recombinant gene expression may be driven by the SV40 early promoter/enhancer within the vector. The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 2. -
FIG. 1C depicts an expression vector used for the expression of a single chain protein in CHO DG44 cells. Preferably, a dicistronic expression cassette with a recombinant gene in the 1st cistron followed by a DHFR gene in the 2nd cistron is described in this example. The gene expression in this vector is preferably driven by SV40 early promoter or enhancer. The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 3. -
FIG. 1D depicts a pNeuMAB, which is a dual expression vector containing two cloning cassettes to insert heavy and light chain genes into a single vector. This expression vector has two gene expression cassettes for the insertion of multiple recombinant genes. Each cassette includes an SV40 early promoter and downstream poly A sequence. Each gene is driven by driven SV40 promoter without an enhancer sequence. This expression vector is suitable for expression of light and heavy chains expression of the antibodies. The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 4. -
FIG. 1E depicts a further expression vector, pNeuMAB-IRES-DHFR, for high level expression of heavy and light chains of a recombinant monoclonal antibody on a single vector driven one SV40 promoter and enhancer. This expression vector may be used for the expression of light and heavy antibody chains. This expression vector generally includes two gene expression cassettes for insertion of recombinant genes. Each cassette consists of SV40 early promoter/enhancer and downstream poly A sequence. Heavy chain and light chain are inserted in 1st and 2nd cassettes respectively. The 2nd cassette is dicistronic having light chain followed by DHFR downstream of IRES. The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 5. -
FIG. 1F depicts a further expression vector, pNeuMAB-IRES-DHFR-(CMV), for high level expression of heavy and light chains of recombinant monoclonal antibody on a single vector driven by CMV and SV40 promoters of heavy and light chains of antibodies respectively. The DHFR gene is driven by IRES downstream of light gene; for the expression of heavy and light chains of antibody in opposite orientations with respect to each other. Heavy chain is driven by CMV promoter whereas light chain is driven by SV40 promoter/enhancer. Light chain and DHFR gene have a dicistronic configuration with DHFR downstream of IRES. The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 6. -
FIG. 1G depicts a further expression vector, pMAB-LC (ires-dhfr), for expression of only light chains (LC) of antibodies. A discistronic cassette for cloning LC in 1st cistron and DHFR in 2nd cassette downstream of IRES. The vector is used in co-transfection with pMAB HC, which is the expression vector shown inFIG. 1H . The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 7. -
FIG. 1H depicts a further expression vector, pMAB-HC, for expression of only heavy chain (HC) of antibodies. Both pMAB-LC and pMAb-HC are co-transfected for expression of complete antibody. The genetic sequence for this expression vector has been submitted along with this application and is designated SEQ. ID No. 8. - A further graph is shown in
FIG. 2 . The graph ofFIG. 2 represents the: Growth of DG44 Cell Lines expressing IGF-1 or hGH compared to the Parental DG44 Cell Line and a Mock Cell Line. A control (mock) cell line is derived from the Parental Cell Line which has been stably transfected with a DNA plasmid containing the selection marker but without the Gene Of Interest (GOI). - The preferred NeuCHO Cell Line demonstrates superior growth advantage compared to the original Parental DG44 Cell Line. In this example, the growth of NeuCHO cells demonstrates higher viable cell densities to that of a DG44 Cell Line expressing the IGF-1 gene.
- This graph shows that when DG44 cells express human Growth Hormone, (Line Graphs E and F), the cells have a very high Maximum Viable Cell Density (up to 425%) compared to the untransfected DG44 Parental Cell Line, the Mock transfected Cell Line, and DG44 Cell Lines expressing high or Low IGF-1 protein.
- The NeuCHO Cell Line has an Integral Cell Density of up to 3.67×107 cell/day/mL, which is 230% that of the Parental DG44 Cell Line, 1.57×107 cell/day/mL.
- Also in
FIG. 2 , the Viable Cell Density is plotted on the Y-axis in cells/mL, and the number of days in culture is plotted on the X-axis. Six line graphs are shown in the figure, namely line graph A, B, C, D, E and F. - Line A represents the growth pattern of a parental DG44 cell line that is not transfected with DNA.
- Line B represents the growth pattern of a parental DG44 cell line that was transfected with a DNA plasmid containing the selection marker but without the Gene Of Interest (GOI).
- Line C represents the growth pattern of a parental DG44 cell line that was stably transfected with a DNA plasmid containing both the selection marker and the Gene Of Interest (GOI). The GOI here is Insulin-like growth factor 1 (IGF-1).
- Line D represents the growth pattern of a parental DG44 cell line that was stably transfected with a DNA plasmid containing both the selection marker and the Gene Of Interest (GOI). The GOI here is Insulin-like growth factor 1 (IGF-1).
- Line E represents the growth pattern of a parental DG44 cell line that was stably transfected with a DNA plasmid containing both the selection marker and the Gene Of Interest (GOI). The GOI here is human Growth Hormone (hGH).
- Line F represents the growth pattern of a parental DG44 cell line that was stably transfected with a DNA plasmid containing both the selection marker and the Gene Of Interest (GOI). The preferred GOI in this example is human Growth Hormone (hGH).
- In
FIG. 3 , a further graph is depicted comparing the integral of viable cell densities (IVCD) of NeuCHO with the standard CHO DG44 cells. This figure demonstrates the difference in the Integral of Viable Cell Densities achieved with the parent cell line NeuCHO compared to parental CHO. - The NeuCHO cell line is superior in growth capabilities and this translates into a more efficient production process which can minimize costs by having higher productions rates, fewer production runs, thus lower productions costs, lower Cost of Goods (COGS).
- Growth and productivity of NeuCHO cell line expressing a recombinant mAB.
- The preferred NeuCHO cell line demonstrates high titre of mAB x compared to traditional CHO expression system.
-
FIG. 5 demonstrates in graphical form that NeuCHO cells may have greater stable transfection efficiency than CHO cells (such CHO DG44 cells). Cells (NeuCHO and CHO) were transfected with DNA encoding mAB ‘x’ prior to selection and single cell cloning from a stable pool. The data is shown inFIG. 5 and demonstrates that stable transfection of NeuCHO cells results in a greater number of clones with high productivity than that of standard CHO cells. The graph shows the levels of various protein expressed in relative quantities at a given time. - NeuCHO cells have an integral of viable cell density that is about 230% greater than CHO DG44 cell lines. CHO DG44 cell lines expressing insulin like growth factor 1 (IGF-1) do not demonstrate the ability to grow to high cell densities as NeuCHO cell lines may generally achieved. NeuCHO cells have a generally greater transfection efficiency than CHO DG44 cells. The survival rate of transfected NeuCHO cells is generally greater then transfected CHO DG44 cells. Additionally, transfection of NeuCHO cells may result in a greater number of clones with a higher productivity than that of standard CHO DG44 cells.
- Preferably, the expression system and vectors described herein may be able to allow or facilitate CHO cells such NeuCHO or CHO DG44 cells to produce desired proteins suitable for pharmaceutical preparation including, but not limited to: Infliximab tumour necrosis factor (referred to as Remicab™); Adalimumab tumour necrosis factor (referred to as Humira™); Etanercept tumour necrosis factor (referred to as Enbrel™); Rituximab CD20 (referred to as Rituxan™ & MabThera™); Bevacizumab vascular endothelial growth factor (referred to as Avastin™); Trastuzumab HER2 (referred to as Herceptin™); Ranibizumab vascular endothelial growth factor (referred to as Lucentism); Cetuximab epidermal growth factor receptor (referred as Erbitux™); Erythropoietin a; Interferon α-Pegylated interferon alfa-2a; Interferon α-Pegylated interferon alfa-2b and hGH.
- NeuCHO cells when used as feeder layer may also increase efficiency of single cell cloning. NeuCHO cells were seeded in single wells of microtitre plates prior to single cell cloning of a stable transfected pool. Secretion of human growth hormone secreted from NeuCHO cells results in an increased survival rate of single cells following Limiting Dilution Cloning.
- Although the invention has been described with reference to specific examples, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms, in keeping with the broad principles and the spirit of the invention described herein.
- The present invention and the described preferred embodiments specifically include at least one feature that is industrial applicable.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/211,625 US20220002776A1 (en) | 2013-03-08 | 2021-03-24 | Cell Expression System |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013900804A AU2013900804A0 (en) | 2013-03-08 | A cell expression system | |
AU2013900808A AU2013900808A0 (en) | 2013-03-08 | A cell expression system | |
AU2013900804 | 2013-03-08 | ||
AU2013900808 | 2013-03-08 | ||
PCT/AU2014/000129 WO2014134657A1 (en) | 2013-03-08 | 2014-02-17 | A cell expression system |
US201514773287A | 2015-09-04 | 2015-09-04 | |
US15/148,930 US9957541B2 (en) | 2013-03-08 | 2016-05-06 | Cell expression system |
US15/802,887 US20180195102A1 (en) | 2013-03-08 | 2017-11-03 | Cell expression system |
US16/228,424 US20200040371A1 (en) | 2013-03-08 | 2018-12-20 | Cell expression system |
US17/211,625 US20220002776A1 (en) | 2013-03-08 | 2021-03-24 | Cell Expression System |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/228,424 Continuation US20200040371A1 (en) | 2013-03-08 | 2018-12-20 | Cell expression system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220002776A1 true US20220002776A1 (en) | 2022-01-06 |
Family
ID=51490471
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/773,287 Expired - Fee Related US9404078B2 (en) | 2013-03-08 | 2014-02-17 | Cell expression system |
US15/148,930 Active US9957541B2 (en) | 2013-03-08 | 2016-05-06 | Cell expression system |
US15/802,887 Abandoned US20180195102A1 (en) | 2013-03-08 | 2017-11-03 | Cell expression system |
US16/228,424 Abandoned US20200040371A1 (en) | 2013-03-08 | 2018-12-20 | Cell expression system |
US17/211,625 Abandoned US20220002776A1 (en) | 2013-03-08 | 2021-03-24 | Cell Expression System |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/773,287 Expired - Fee Related US9404078B2 (en) | 2013-03-08 | 2014-02-17 | Cell expression system |
US15/148,930 Active US9957541B2 (en) | 2013-03-08 | 2016-05-06 | Cell expression system |
US15/802,887 Abandoned US20180195102A1 (en) | 2013-03-08 | 2017-11-03 | Cell expression system |
US16/228,424 Abandoned US20200040371A1 (en) | 2013-03-08 | 2018-12-20 | Cell expression system |
Country Status (10)
Country | Link |
---|---|
US (5) | US9404078B2 (en) |
EP (1) | EP2964768B1 (en) |
JP (1) | JP6464100B2 (en) |
KR (1) | KR20150125994A (en) |
AU (2) | AU2014225272B2 (en) |
CA (1) | CA2904146C (en) |
MY (1) | MY186731A (en) |
PL (1) | PL2964768T3 (en) |
SG (1) | SG11201506926SA (en) |
WO (1) | WO2014134657A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US20160017277A1 (en) * | 2013-03-08 | 2016-01-21 | Neuclone Biologics Pty Ltd | Cell culture media composition and methods of producing thereof |
AU2014225272B2 (en) | 2013-03-08 | 2015-10-22 | Neuclone Biologics Pty Ltd | A cell expression system |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015195049A1 (en) * | 2014-06-18 | 2015-12-23 | Agency For Science, Technology And Research | Novel promoters for high level expression |
PT3167065T (en) * | 2014-07-09 | 2020-07-01 | Lupin Ltd | Dual cistronic bacterial expression system |
CN105820246A (en) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | Method for preparing novel recombinant anti-TNF alpha chimeric monoclonal antibody and application thereof |
ES2823173T3 (en) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Hybrid promoter and uses of it |
US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
AU2017211359A1 (en) * | 2016-01-27 | 2018-08-02 | Total Raffinage Chimie | Multigene expression in microalgae |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US772031A (en) * | 1904-05-14 | 1904-10-11 | Edward Ermold | Envelop. |
IL102929A (en) | 1992-08-24 | 1996-11-14 | Interpharm Lab Ltd | Serum-free medium for mammalian cells |
AUPN442295A0 (en) | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
IL140110A0 (en) | 2000-12-05 | 2002-02-10 | Applied Research Systems | Improvement of homogeneity and secretion of recombinant proteins in mammalian systems |
WO2003046162A2 (en) * | 2001-11-28 | 2003-06-05 | Polymun Scientific Immunbiologische Forschung Gmbh | Process for the production of polypeptides in mammalian cell cultures |
WO2003106658A2 (en) | 2002-06-18 | 2003-12-24 | Zymogenetics, Inc. | Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter |
US8669109B2 (en) | 2003-08-19 | 2014-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods of producing proteins in Chinese hamster ovary (CHO) cells |
US7919270B2 (en) | 2003-09-09 | 2011-04-05 | Acyte Biotech Pty Ltd | Mammalian expression system |
KR100772031B1 (en) * | 2005-10-22 | 2007-10-31 | (주)리즈바이오텍 | Increasing production of recombinant protein by growth hormone |
EP2294080A2 (en) | 2008-06-27 | 2011-03-16 | Novo Nordisk Health Care AG | N-glycosylated human growth hormone with prolonged circulatory half-life |
AU2014225272B2 (en) | 2013-03-08 | 2015-10-22 | Neuclone Biologics Pty Ltd | A cell expression system |
US20160017277A1 (en) | 2013-03-08 | 2016-01-21 | Neuclone Biologics Pty Ltd | Cell culture media composition and methods of producing thereof |
-
2014
- 2014-02-17 AU AU2014225272A patent/AU2014225272B2/en active Active
- 2014-02-17 CA CA2904146A patent/CA2904146C/en active Active
- 2014-02-17 EP EP14761184.2A patent/EP2964768B1/en active Active
- 2014-02-17 KR KR1020157027065A patent/KR20150125994A/en not_active IP Right Cessation
- 2014-02-17 SG SG11201506926SA patent/SG11201506926SA/en unknown
- 2014-02-17 JP JP2015560486A patent/JP6464100B2/en not_active Expired - Fee Related
- 2014-02-17 WO PCT/AU2014/000129 patent/WO2014134657A1/en active Application Filing
- 2014-02-17 PL PL14761184T patent/PL2964768T3/en unknown
- 2014-02-17 US US14/773,287 patent/US9404078B2/en not_active Expired - Fee Related
- 2014-02-17 MY MYPI2015702978A patent/MY186731A/en unknown
-
2016
- 2016-01-22 AU AU2016200361A patent/AU2016200361B2/en active Active
- 2016-05-06 US US15/148,930 patent/US9957541B2/en active Active
-
2017
- 2017-11-03 US US15/802,887 patent/US20180195102A1/en not_active Abandoned
-
2018
- 2018-12-20 US US16/228,424 patent/US20200040371A1/en not_active Abandoned
-
2021
- 2021-03-24 US US17/211,625 patent/US20220002776A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2014225272B2 (en) | 2015-10-22 |
AU2014225272A1 (en) | 2015-09-24 |
US20200040371A1 (en) | 2020-02-06 |
JP6464100B2 (en) | 2019-02-06 |
EP2964768A1 (en) | 2016-01-13 |
SG11201506926SA (en) | 2015-09-29 |
CA2904146C (en) | 2023-03-21 |
US9957541B2 (en) | 2018-05-01 |
CA2904146A1 (en) | 2014-09-12 |
AU2016200361A1 (en) | 2016-02-11 |
US20180195102A1 (en) | 2018-07-12 |
MY186731A (en) | 2021-08-14 |
EP2964768B1 (en) | 2020-07-22 |
KR20150125994A (en) | 2015-11-10 |
US9404078B2 (en) | 2016-08-02 |
PL2964768T3 (en) | 2021-01-11 |
AU2016200361B2 (en) | 2017-12-14 |
US20160244799A1 (en) | 2016-08-25 |
US20180100176A9 (en) | 2018-04-12 |
US20160017281A1 (en) | 2016-01-21 |
JP2016510592A (en) | 2016-04-11 |
EP2964768A4 (en) | 2016-11-09 |
WO2014134657A1 (en) | 2014-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220002776A1 (en) | Cell Expression System | |
EP3075858B1 (en) | Mammalian expression vector | |
JP5801207B2 (en) | Expression vector system containing two types of selectable markers | |
CN111971388B (en) | Methods of cell selection and modification of cell metabolism | |
KR20100017923A (en) | Method for manufacturing a recombinant polyclonal protein | |
KR102647165B1 (en) | A universal self-regulating mammalian cell line platform for biologics production | |
CN101511994A (en) | Protein production using eukaryotic cell lines | |
EP1997892A1 (en) | Screening for expressible transfectants in a eukaryotic system | |
EP2401383B1 (en) | Methods for selecting eukaryotic cells expressing a heterologous protein | |
US11781146B2 (en) | Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element | |
EP1957660B1 (en) | Materials and methods to increase peptide chain expression | |
EP3382029B1 (en) | Recombinant mammalian cells and method for producing substance of interest | |
JP5811321B2 (en) | Novel protein expression method | |
Sharfstein | Novel Approaches For Obtaining High-productivity Clones | |
Wurm et al. | Transient Gene Expression: A Novel Mammalian Cell-Based Technology for Recombinant Protein Production: A historical and technical perspective | |
Ozanne | Getting the most out of producing therapeutic biologics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUNYETTE PTY LTD, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUCLONE PTY LIMITED;REEL/FRAME:056536/0462 Effective date: 20131108 Owner name: NEUCLONE BIOLOGICS PTY LTD, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUNYETTE PTY LTD;REEL/FRAME:056536/0449 Effective date: 20140623 Owner name: NEUCLONE PTY LIMITED, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUNSTROM, NOELLE;REEL/FRAME:056536/0514 Effective date: 20130315 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |